Aim: Our objective is to enhance the molecular diagnostic precision in a cohort of unresolved monogenic diabetes cases, previously investigated by next-generation sequencing target panel (tNGS), through comprehensive bidirectional phenotypic and genotypic reanalysis. Methods: We analyzed molecular and clinical data from 128 unresolved cases referred between 2011 and 2019. These included 92 cases suspected of maturity-onset diabetes of the young (MODY), 12 of neonatal diabetes, 16 of familial partial lipodystrophy (FPLD), 7 of mitochondrial diabetes, and 1 of Wolfram syndrome. All cases were initially investigated using a tNGS panel comprising 51 nuclear genes and the complete mitochondrial genome. Results: Our extensive reanalysis process enhanced molecular diagnostic yields from 9 to 26%. Phenotypic reevaluation, entailing in-depth phenotyping, was instrumental in excluding 62 (48.4%) atypical cases. Genotypic reanalysis identified 5 previously overlooked molecular defects: two mutations in regulatory regions (one in the HNF1A promoter and another in the PTF1A enhancer); one in the MTTK mitochondrial gene; one in the MFN2 gene; and one in the GCK gene. Conclusions: Our findings indicate that a combined approach of genotypic and phenotypic reanalysis is an effective strategy for improving molecular diagnostic accuracy in individuals with suspected monogenic diabetes.
No takes yet. Share an insight, caveat, or question.
Teles et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: